Health Care

Mark Lappe’s hefty buy‑in of 2.5 million Inhibrx shares amid a market dip signals strong insider confidence and could spark a rebound if upcoming trial data deliver.

CEO Atay Oguzhan’s Rule 10b5‑1 trades reveal a disciplined, long‑term buy‑low, sell‑high strategy that signals confidence in BillionToOne’s upside while mitigating insider‑trading risks.

Insider sales of Codexis stock on Oct 12, 2026 highlight volatility and potential undervaluation—analyzing RSU timing, market sentiment, and value‑investor insights.

Winklevoss Capital adds 5 M CYPHERPUNK shares at zero cost, boosting its 9.5% stake—an insider move hinting at long‑term confidence amid volatile stock prices.

CEO Martine Rothblatt’s 10 b5‑1 plan at United Therapeutics shows disciplined buying/selling that boosts liquidity yet keeps her holdings strong—no insider edge, just a clear long‑term strategy.

Mitchell Rales sells 500k Danaher shares amid board expansion—insider move signals potential confidence or portfolio shift for investors watching the stock.

Investor Insight: Susan Burwig’s latest MEDPACE shares buy signals top‑tier confidence and highlights growth prospects amid rising stock momentum.

Insider buy by Nurix director Gregory Julia P. signals confidence amid a 135% annual gain and rising pipeline—watch the stock’s future upside.

Inside Summit Therapeutics’ 2026 insider buy: CFO Anand Bhaskar buys 100k shares at zero cost, signaling long‑term confidence amid market volatility and a hopeful pipeline.

Insider buys at Mirum Pharm signal optimism ahead of LIVMARLI sNDA; executives’ equity timing hints at future revenue growth and potential valuation lift.